Window Trial 5-aza in HNSCC, T-tare
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 20
Summary
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 99 years
- Gender
- Both males and females
Description
Primary Objectives: The primary objectives of this study are: • to determine the proportion of HPV-positive patients in whom 5-azacytidine increases APOBEC RNA expression. Secondary Objectives The secondary objectives of this study are: to investigate response (proliferation, apoptosis), as well as ...
Primary Objectives: The primary objectives of this study are: • to determine the proportion of HPV-positive patients in whom 5-azacytidine increases APOBEC RNA expression. Secondary Objectives The secondary objectives of this study are: to investigate response (proliferation, apoptosis), as well as reactivation of IFN pathways in patients treated with 5-azacitadine for HPV-positive and HPV-negative HNSCC. to investigate the clinical activity of 5-azacitadine in patients with HPV-positive and HPV-negative HNSCC. to investigate the safety of 5-azacitadine in patients with HPV-positive and HPV-negative HNSCC
Tracking Information
- NCT #
- NCT02178072
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Barbara Burtness, MD Yale University School of Medicine, Smilow Cancer Center at Yale New Haven Hospital, Yale Comprehensive Cancer Center
Get Well Soon